Showing 1 - 5 results of 5 for search 'Daniel C. Cho', query time: 0.03s Refine Results
  1. 1
    Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma

    Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma by Andrey Moiseyenko, Franco Muggia, Thomas Condamine, Jennifer Pulini, John E. Janik, Daniel C. Cho

    Published 2020-11-01
    Get full text
    Article
  2. 2
    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors by Rebecca Kristeleit, Juan Martin-Liberal, Kristen Spencer, Janice M Mehnert, Maria Vieito, Elizabeth J Davis, Angela Orcurto, Thomas Condamine, Daniel C Cho, Jennifer Pulini, Rowan E Miller, Sarah P Blagden, Dominik Berthold, Dana B Cardin, Prashanth Hari Dass, John E Janik, Jason Clark, Xuejun Chen

    Published 2022-10-01
    Get full text
    Article
  3. 3
    Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

    Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study by Mario Sznol, Adi Diab, Jonathan Zalevsky, Ute Hoch, Mehmet A Bilen, Giovanni Grignani, Nizar M Tannir, Erika Puente, Arjun V Balar, Daniel C Cho, Arlene O Siefker-Radtke, Lily Tang, David Chien, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Michael E Hurwitz

    Published 2022-04-01
    Get full text
    Article
  4. 4
    Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

    Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors by Mario Sznol, Michael Yellin, Tibor Keler, Jose Lutzky, Amy Weise, Margaret K Callahan, Osama Rahma, Rachel E Sanborn, Alexander Starodub, Deepa S Subramaniam, Antonio Jimeno, Tracey Rawls, David A Reardon, Daniel C Cho, Rhonda L Bitting, Michael J Pishvaian, Branimir I Sikic, Naiyer A Rizvi, Julie E Bauman, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Jeanny B Aragon-Ching, Thomas R Hawthorne

    Published 2022-08-01
    Get full text
    Article
  5. 5
    First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

    First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore

    Published 2023-03-01
    Get full text
    Article

Search Tools: